Anuh Pharma profit and loss

Latest FY26

Revenue: ₹772cr+16.7% on FY25
EBITDA: ₹61.7cr+1.3% on FY25
Net profit: ₹41.0cr−13.3% on FY25
EPS: ₹4.10−56.6% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025

Expenses
	779	772	662
	6.9	4.4	9.5
	786	776	671
	547	510	463
	56.8	79.2	38.5
	−8.0	10.0	−2.5
	27.4	26.3	23.0
	0.3	0.5	0.6
	11.3	11.4	8.7
	91.4	84.0	78.2
	726	722	610
	64.9	61.7	60.9
	53.6	50.3	52.2
Profit
	60.2	54.2	61.0
	60.2	54.2	61.0
	16.7	15.0	15.3
	−0.6	−1.8	−1.7
	16.0	13.2	13.7
	44.2	41.0	47.4
	44.2	41.0	47.4
	0.2	0.2	−0.0
	44.4	41.2	47.3
Per share
	₹4.41	₹4.10	₹9.45
	₹4.41	₹4.10	₹9.45
Other comprehensive income — detail
	0.2	0.2	−0.0
	0.3	0.2	−0.0
	0.1	0.1	−0.0
Per share — as-filed variants
	₹4.41	₹4.10	₹9.45
	₹4.41	₹4.10	₹9.45
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	184	172	162
	23.6%	22.3%	24.5%
Adjusted (ex-exceptional items) — derived
	60.2	54.2	61.0
	44.2	41.0	47.4
	₹4.41	₹4.10	₹9.45

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

ANUHPHR₹79.61

Anuh Pharma Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersAHCL WANBURY ZIMLAB BAJAJHCARE THEMISMED LINCOLN VALIANTLAB SIGACHIMcap ₹798 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	661.5	771.7	779.0
Other Income	9.5	4.4	6.9
Total Income	671.0	776.0	785.9
Expenses
+ Cost of Materials Consumed	463.3	510.4	546.5
+ Purchases of Stock-in-Trade	38.5	79.2	56.8
+ Changes in Inventories	-2.5	10.0	-8.0
+ Employee Benefit Expense	23.0	26.3	27.4
+ Finance Costs	0.6	0.5	0.3
+ Depreciation & Amortisation	8.7	11.4	11.3
+ Other Expenses	78.2	84.0	91.4
Total Expenses	610.0	721.8	725.7
EBITDA	60.9	61.7	64.9
EBIT	52.2	50.3	53.6
Profit
PBT before Exceptional Items	61.0	54.2	60.2
Pretax Income	61.0	54.2	60.2
+ Current Tax	15.3	15.0	16.7
+ Deferred Tax	-1.7	-1.8	-0.6
Tax Expense	13.7	13.2	16.0
Net Income	47.4	41.0	44.2
+ Net Income — Continuing Ops	47.4	41.0	44.2
+ Other Comprehensive Income	-0.0	0.2	0.2
Total Comprehensive Income	47.3	41.2	44.4
Per Share
Basic EPS	9.45	4.10	4.41
Diluted EPS	9.45	4.10	4.41
Other Comprehensive Income — detail
+ Other Comprehensive Income	-0.0	0.2	0.2
+ Items NOT to be Reclassified to P&L	-0.0	0.2	0.3
+ Tax on Items NOT to be Reclassified	-0.0	0.1	0.1
Per Share — as-filed variants
Basic EPS — Continuing Operations	9.45	4.10	4.41
Diluted EPS — Continuing Operations	9.45	4.10	4.41
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	162.1	172.0	183.6
Gross Margin %	24.51	22.29	23.57
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	61.0	54.2	60.2
Net Income Adj (tax-effected)	47.4	41.0	44.2
EPS Adj	9.45	4.10	4.41
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	5.00	5.00	5.00
Paid Up Equity Capital	25.1	50.1	50.1

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.